Latest News

(UroToday.com) The clinical benefit of radium-223 has been demonstrated in patients with metastatic castration resistant prostate cancer (mCRPC) in the ALSYMPCA randomized placebo controlled trial.1 Over the last nearly decade since publication of this landmark trial, combination therapy in patients with mCRPC is of great interest for improving efficacy but must be done in a safe […]

(UroToday.com) During the Best of Journals: Urothelial Cancer Session at the 2021 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, Dr. Lindsey Herrel provided the surgical/urology perspective, highlighting what she felt to be the key papers published in urothelial cancer in the past year, emphasizing three key themes: new and emerging approaches to the treatment […]

(UroToday.com) During the Best of Journals: Urothelial Cancer Session at the 2021 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, Dr. Abhishek Solanki provided the radiation oncology perspective, highlighting what he felt to be the key papers published in urothelial cancer in the past year, highlighting four main themes:

(UroToday.com) During the Best of Journals: Urothelial Cancer Session at the 2021 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, Dr. Scot Niglio provided the medical oncology perspective, highlighting what he felt to be the four key papers published in urothelial cancer in the past year.

(UroToday.com) At the 2021 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium during the session on practical applications of novel imaging and genomic approaches in the management of clinically localized prostate cancer, Dr. Anuradha Gopalan discussed redefining high-risk prostate cancer beyond clinical parameters. Dr. Gopalan notes that in the latest National Comprehensive Cancer Network […]

Cohort-based germline variant characterization is the standard approach for pathogenic variant discovery in clinical and research samples. However, the impact of cohort size on the molecular diagnostic yield of joint genotyping is largely unknown.

Nowadays, the partial nephrectomy (PN) not only is considered oncological equivalent to radical nephrectomy as renal tumor’s treatment, but has also give benefits in quality of life and overall survival of patients.

KIRC is one of the most common cancers with a poor prognosis. ACE2 was involved in tumor angiogenesis and progression in many malignancies. The role of ACE2 in KIRC is still ambiguous. Various bioinformatics analysis tools were investigated to evaluate the prognostic value of ACE2 and its association with immune infiltration in KIRC.

Prostate cancer is common, particularly in older patients, as the risk of getting prostate cancer increases with age. Cancer therapy brings unique challenges in older patients, as this population is vulnerable to many side effects and drug interactions, and they have varying degrees of frailty, which may limit the use of these therapies.

To assess the role of multi-parametric MRI (mpMRI) in assessment of tumor response to fluvastatin administered prior to radical prostatectomy. Men with MRI-visible, clinically significant prostate cancer and due to be treated with radical prostatectomy were prospectively enrolled.